Dr. Aaron P. Rapoport

• 
  www.ummsfoundation.org/jobson/success_story.htm - [Cached Version]
  Published on: 6/27/2008    Last Visited: 10/4/2008  

  Video:Gary Jobson Talks with Dr. Aaron Rapoport about Research and Treatment for Blood Cancers
  
  "I had my transplant in 2003 under Dr. Rapoport's excellent care," he says."It was a very difficult process, and I had some complications along the way due to the very aggressive nature of the treatments I was undergoing.It took two years to get my disease into remission, but I survived.I can't say enough about the nurses and other staff who took care of me while I was at the cancer center," he says.
  ...
  "During my two years of treatment, I had an opportunity to learn about Dr. Rapoport's research activities.
  ...
  His latest effort is leading a major fundraising campaign to support Dr. Rapoport's work.
  ...
  For information on making a gift to support Dr. Rapoport's cancer research, please contact Susan O'Connell at the UMMS Foundation at 410-328-7719.

• 
  www.sciencedaily.com/videos/2006/0308-beating_bone_marr - [Cached Version]
  Published on: 3/1/2006    Last Visited: 7/12/2009  

  Aaron Rapoport, a hematologist and oncologist at the University of Maryland Greenebaum Cancer Center in Baltimore, says, "What we're seeking to do is to harness the power of the patient's own immune system."

• 
  www.cancer-feed.com/view/112/22305/_Aaron_Rapoport_Hono - [Cached Version]
  Published on: 6/5/2006    Last Visited: 5/11/2007  

  Aaron Rapoport, M.D., associate professor of Medicine at the University of Maryland School of Medicine and a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, has been selected by The Leukemia & Lymphoma Society to receive the Stohlman Scholar Award recognizing outstanding contributions to the advancement of blood cancer research.From: UM Greenebaum Cancer Center News (Latest news regarding cancer research and treatments at the University of Maryland Greenebaum Cancer Center.)

• 
  www.ummsfoundation.org/jobson/rapoport_biography.htm - [Cached Version]
  Published on: 10/4/2008    Last Visited: 10/4/2008  

  Dr. Aaron Rapoport
  ...
  Aaron P. Rapoport, Ph.D. Professor of MedicineDirector, Gene Medicine/Lymphoma

• 
  www.accessmedicine.com/amed/public/amed_news/news_artic - [Cached Version]
  Published on: 4/23/2002    Last Visited: 11/13/2002  

  "This type of low-grade follicular lymphoma has traditionally been highly treatable, but essentially incurable," says Aaron P. Rapoport, M.D., the director of lymphoma-gene medicine at the Greenebaum Cancer Center and the chief investigator for the study."This technique for harnessing the immune system may result in long-term disease remission and potential cures for some patients."
  
  So far, four people have been enrolled in the study at the Greenebaum Cancer Center, but researchers hope to recruit a total of 12 to 15 patients in the Phase III clinical trial.The first patient to be vaccinated, a 45-year-old Baltimore woman, started her treatment earlier this month after completing a course of chemotherapy.
  
  About 480 patients are expected to participate in the nationwide study at 25 institutions in the United States and Canada.
  ...
  Lymphomas and other types of cancers use mechanisms to evade the body's immune system," says Dr. Rapoport, an associate professor of medicine at the University of Maryland School of Medicine.
  
  He said that in earlier clinical trials, about two-thirds of the patients showed positive immunological responses to the vaccinations."But it is difficult to know the clinical impact of that," he says."Does it mean that they have better responses or longer-lasting responses?That's what this study is designed to show."
  
  In this trial, patients first receive eight rounds of chemotherapy with three drugs - cytoxan, vincristine, and prednisone.If they experience at least a 50% remission, they remain in the study and are observed for another five months while their bodies rest from the chemotherapy.If there is still no progression of their disease, two-thirds of the patients receive a vaccine crafted from their own tumor cells, plus an immune system stimulant, while one-third receive a vaccine using only a carrier protein and the stimulant, which may also activate the immune system in a beneficial way.
  ...
  Low-grade follicular lymphomas are generally treated with radiation if they are localized or chemotherapy if they are widespread, Dr. Rapoport says.The cancer responds well to treatment, but is likely to recur.
  
  "I believe this technology offers the potential for better treatment results than we have previously seen," Dr. Rapoport says.
  
  Related Chapters:Harrisons Chapter 112: Malignancies of Lymphoid CellsHarrisons Chapter 79: Approach to the Patient With Cancer

• 
  www.ww.lls.org/all_cal_detail.adp?item_id=469000 - [Cached Version]
  Published on: 4/10/2007    Last Visited: 4/10/2007  

  This program will feature Judith E. Karp, M.D., professor of Oncology and Medicine, director, Leukemia Program, B. Douglas Smith, M.D., associate professor, Hematologic Malignancies both from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Aaron P. Rapoport, M.D., professor of Medicine, director, Gene Medicine/Lymphoma University of Maryland Medical Center, Baltimore MD.

• 
  www.kycancerc.org/ - [Cached Version]
  Published on: 5/9/2007    Last Visited: 5/9/2007  

  This free teleconference will feature Judith E. Karp, M.D., professor of Oncology and Medicine, director, Leukemia Program, B. Douglas Smith, M.D., associate professor, Hematologic Malignancies both from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Aaron P. Rapoport, M.D., professor of Medicine, director, Gene Medicine/Lymphoma University of Maryland Medical Center, Baltimore MD. Participants will have the opportunity to ask questions during the program.

• 
  7/9 - Marrow and Stem Cell Transplant Study - [Cached Version]
  Published on: 7/9/2001    Last Visited: 10/27/2006  

  "In the case of myeloma, treatment with high-dose chemotherapy followed by autologous stem cell transplant using the patient's own stem cells is considered to be the best therapy currently available," says Aaron Rapoport, M.D., associate professor of medicine at the University of Maryland School of Medicine and director of Lymphoma-Gene Medicine at the University of Maryland Greenebaum Cancer Center.
  ...
  "This treatment is thought to provide a critical second signal to the cells that is otherwise lacking in patients with certain types of cancers," explains Dr. Rapoport.Another interesting objective of the myeloma study is to look at whether a new vaccine for chickenpox might also be beneficial for myeloma patients undergoing a bone marrow transplant.
  
  Shingles occurs in up to one-third of patients who have an autologous transplant for various hematologic malignancies.It causes a painful skin rash that sometimes spreads to other tissues and organs, such as the eyes, lungs, liver and nervous system.
  
  "This new vaccine may boost the patient's immunity to the chickenpox virus and thereby prevent shingles, which can cause severe pain and, occassionally, life-threatening complications," says Dr. Rapoport.
  ...
  "Allogeneic or "donor" transplants are not available to many patients with these diseases," says Dr. Rapoport.
  ...
  Dr. Rapoport has been selected to receive a Leukemia & Lymphoma Society Scholar in Clinical Research Award to help fund these research studies.

• 
  Ask the Expert - [Cached Version]
  Published on: 3/15/2009    Last Visited: 3/15/2009  

  Leukemia, Chronic Myelogenous (CML) - Dr. Aaron Rapoport (See Q&A Archive)

• 
  Beth Tfiloh Dahan Community School E-tone - [Cached Version]
  Published on: 3/31/2006    Last Visited: 12/24/2007  

  Dr. Aaron Rapoport, Research Physician at the University of Maryland School of Medicine, delivered a thoughtful and inspiring keynote address on the role of science and medicine in the Jewish community.

Page:  1 2 3 4 5